On Jun 29, 2018 135.17 % to Target, Global Blood Therapeutics (GBT) Stock “Buy” Rating Maintained by Nomura.

June 29, 2018 - By Jeanette Garcia

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Corporate Logo

Reiterated Global Blood Therapeutics (GBT) Rating.

Global Blood Therapeutics (GBT) had $109 target given by Nomura in analysts report published on 28 June. Professional analysts’s PT suggests a potential upside of 135.17 % from the company’s close price.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Ratings Coverage

In total 10 analysts cover Global Blood Therapeutics (GBT). “Buy” rating has 9, “Sell” are 0, while 1 are “Hold”. 90% are bullish. 25 are the (GBT)’s analyst reports since January 11, 2018 according to StockzIntelligence Inc. On Monday, March 12 the stock has “Buy” rating by H.C. Wainwright. On Tuesday, May 8 the firm has “Outperform” rating by Oppenheimer given. On Tuesday, March 20 Oppenheimer maintained the shares of GBT in report with “Buy” rating. In Monday, May 21 report Wedbush maintained the stock with “Buy” rating. In Thursday, June 28 report Nomura maintained the stock with “Buy” rating. On Monday, June 18 the stock of Global Blood Therapeutics, Inc. (NASDAQ:GBT) has “Buy” rating given by Wedbush. On Thursday, January 11 the firm has “Buy” rating by H.C. Wainwright given. On Wednesday, February 28 H.C. Wainwright maintained Global Blood Therapeutics, Inc. (NASDAQ:GBT) rating. H.C. Wainwright has “Buy” rating and $73.0 target. On Wednesday, February 28 Oppenheimer maintained Global Blood Therapeutics, Inc. (NASDAQ:GBT) with “Buy” rating. On Wednesday, March 21 Morgan Stanley downgraded the shares of GBT in report to “Equal-Weight” rating.

GBT touched $46.35 during the last trading session after $1.1 change.Global Blood Therapeutics, Inc. has volume of 751,216 shares. Since June 29, 2017 GBT has risen 60.31% and is uptrending. The stock outperformed the S&P 500 by 47.74%.

Global Blood Therapeutics, Inc. (NASDAQ:GBT)’s earnings report is awaited by WallStreet on August, 6, according to Zacks. Analysts predict 58.18 % diference or $-0.87 from the $-0.55 EPS from 2017. Wall Street sees 0.00 % EPS growth as of August, 6.

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood disorders.The firm is worth $2.40 billion. The Company’s lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase III clinical trials in adult and adolescent patients with sickle cell disease .Last it reported negative earnings. The firm is also involved in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trials of adolescent and pediatric patients with SCD; and other research and development activities that are in pre-clinical phase.

For more Global Blood Therapeutics, Inc. (NASDAQ:GBT) news brought out recently go to: Benzinga.com, Seekingalpha.com, Benzinga.com, Seekingalpha.com or Benzinga.com. The titles are as follows: “8 Biggest Price Target Changes For Thursday” brought out on June 28, 2018, “GBT’s voxelotor shows lower treatment effect in adolescents with SCD in mid-stage study; shares slip 4% premarket” on June 15, 2018, “Global Blood Therapeutics Shares Plunge After Sickle Cell Candidate Shows Reduced Effect” with a publish date: June 17, 2018, “Rounds Report: Global Blood Therapeutics Made A Strong Run Due To The Positive Clinical Binary” and the last “Global Blood Therapeutics Meets Primary Endpoints In Sickle Cell Study, Seeks Accelerated FDA Approval” with publication date: June 27, 2018.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.